These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 38391508)
21. Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement. Batista-Duharte A; Sendra L; Herrero MJ; Téllez-Martínez D; Carlos IZ; Aliño SF Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32079263 [No Abstract] [Full Text] [Related]
22. Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry. Terada C; Oh K; Tsubaki R; Chan B; Aibara N; Ohyama K; Shibata MA; Wada T; Harada-Shiba M; Yamayoshi A; Yamamoto T Nat Commun; 2023 Dec; 14(1):7972. PubMed ID: 38042877 [TBL] [Abstract][Full Text] [Related]
23. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity. Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells. Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814 [TBL] [Abstract][Full Text] [Related]
26. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity. Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271 [TBL] [Abstract][Full Text] [Related]
27. Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension. Yasuhara H; Yoshida T; Sasaki K; Obika S; Inoue T Mol Diagn Ther; 2022 Jan; 26(1):117-127. PubMed ID: 34994962 [TBL] [Abstract][Full Text] [Related]
28. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas. Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565 [TBL] [Abstract][Full Text] [Related]
29. Evaluating the efficacy of purchased antisense oligonucleotides to reduce mouse and human tau Vemula P; Schoch KM; Miller TM Front Mol Neurosci; 2023; 16():1320182. PubMed ID: 38192302 [TBL] [Abstract][Full Text] [Related]
30. The powerful world of antisense oligonucleotides: From bench to bedside. Quemener AM; Bachelot L; Forestier A; Donnou-Fournet E; Gilot D; Galibert MD Wiley Interdiscip Rev RNA; 2020 Sep; 11(5):e1594. PubMed ID: 32233021 [TBL] [Abstract][Full Text] [Related]
31. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model. Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231 [TBL] [Abstract][Full Text] [Related]
32. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging. Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690 [TBL] [Abstract][Full Text] [Related]
33. An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Belenkov AI; Paiement JP; Panasci LC; Monia BP; Chow TY Cancer Res; 2002 Oct; 62(20):5888-96. PubMed ID: 12384553 [TBL] [Abstract][Full Text] [Related]
34. Drug Discovery Perspectives of Antisense Oligonucleotides. Kim Y Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811 [TBL] [Abstract][Full Text] [Related]
35. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Linnane E; Davey P; Zhang P; Puri S; Edbrooke M; Chiarparin E; Revenko AS; Macleod AR; Norman JC; Ross SJ Nucleic Acids Res; 2019 May; 47(9):4375-4392. PubMed ID: 30927008 [TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotides: a promising therapeutic option against infectious diseases. Tekintaş Y; Temel A Nucleosides Nucleotides Nucleic Acids; 2024; 43(1):1-39. PubMed ID: 37395450 [TBL] [Abstract][Full Text] [Related]
37. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581 [TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. Kim TW; Kim KS; Seo JW; Park SY; Henry SP J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663 [TBL] [Abstract][Full Text] [Related]
39. G-rich motifs within phosphorothioate-based antisense oligonucleotides (ASOs) drive activation of FXN expression through indirect effects. Wang F; Calvo-Roitberg E; Rembetsy-Brown JM; Fang M; Sousa J; Kartje ZJ; Krishnamurthy PM; Lee J; Green MR; Pai AA; Watts JK Nucleic Acids Res; 2022 Dec; 50(22):12657-12673. PubMed ID: 36511872 [TBL] [Abstract][Full Text] [Related]
40. Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Miller CM; Donner AJ; Blank EE; Egger AW; Kellar BM; Østergaard ME; Seth PP; Harris EN Nucleic Acids Res; 2016 Apr; 44(6):2782-94. PubMed ID: 26908652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]